Vitamin E Combined with Mefenamic Acid versus Mefenamic Acid Alone in Controlling Pain During Primary Dysmenorrhea: A Randomized Controlled Trial
DOI:
https://doi.org/10.61581/mjsp.v6i01.385Keywords:
Primary dysmenorrhea, Vitamin E, Mafenamic acid, Randomized controlled TrialAbstract
Objective: To compare the mean pain score and pain reduction with Vitamin E plus Mefenamic acid versus Mefenamic acid alone for the management of primary dysmenorrhea.
Methods: This 6-month randomized controlled trial was conducted at the Department of Obstetrics and Gynecology, Combined Military Hospital, Multan. Sixty women aged 15–25 years presenting with primary dysmenorrhea were enrolled via non-probability consecutive sampling and randomized into two groups (n = 30 each). Group A received Mefenamic Acid (400 mg) combined with Vitamin E (400 IU), while Group B received Mefenamic Acid (400 mg) alone. Pain was assessed using a 100-mm Visual Analogue Scale (VAS) at baseline and during the second menstrual cycle. Data were analyzed using SPSS version 23. An independent sample t-test was applied to compare mean pain scores, with a P-value ? 0.05 considered significant.
Results: The mean age of the participants was 21.1 ± 3.1 years. Baseline pain scores were comparable between Group A (54.97 ± 7.31) and Group B (53.20 ± 8.12) (P = 0.374). After 4 weeks, the mean post-treatment pain score in Group A (18.53 ± 6.13) was significantly lower than in Group B (34.63 ± 8.10) (P < 0.001). The mean pain reduction was significantly higher in the combination group (36.43 ± 5.45) compared to the Mefenamic acid-only group (18.57 ± 1.59) (P < 0.001).
Conclusion: Vitamin E combined with Mefenamic acid is significantly more effective in reducing menstrual pain than Mefenamic acid alone. Incorporating Vitamin E as an adjunctive therapy offers a safe, enhanced approach to dysmenorrhea management.
Downloads
References
1. Kho KA, Shields JK. Diagnosis and management of primary dysmenorrhea. JAMA. 2020;323(3):268-9.
2. Azagew AW, Kassie DG, Walle TA. Prevalence of primary dysmenorrhea, its intensity, impact and associated factors among female students' at Gondar town preparatory school, Northwest Ethiopia. BMC Womens Health. 2020;20(1):5.
3. Daily JB, As-Sanie S, Smith YR. The impact of dysmenorrhea on academic and social performance: a cross-sectional study. J Pediatr Adolesc Gynecol. 2023;36(2):145-50.
4. Karout S, Fares K, Muqri N, et al. Prevalence and impact of dysmenorrhea on the quality of life among young women in the MENA region: a systematic review. BMC Womens Health. 2022;22(1):432.
5. Nunez-Troconis J, Carvallo D, Martínez-Núñez E. Primary Dysmenorrhea: pathophysiology. Invest Clín. 2021;62(4):378-406.
6. Ferries-Rowe E, Corey E, Archer JS. Primary dysmenorrhea: diagnosis and therapy. Obstet Gynecol. 2020;136(5):1047-58.
7. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2020;1(1):CD001751.
8. Alikamali M, Mohammad-Alizadeh-Charandabi S, Maghalian M, Mirghafourvand M. The effects of vitamin E on the intensity of primary dysmenorrhea: A systematic review and meta-analysis. Clin Nutr ESPEN. 2022;52:50-9.
9. Garcia-Contreras F, Benitez-Guerrero B. NSAIDs and their adverse effects in long-term menstrual pain management: a pharmacological review. Drug Saf. 2021;44(9):921-32.
10. Naz MS, Kiani Z, Fakari FR, Ghasemi V, Abed M, Ozgoli G. The effect of micronutrients on pain management of primary dysmenorrhea: a systematic review and meta-analysis. J Caring Sci. 2020;9(1):47-56.
11. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pills and combined therapies for dysmenorrhea: an updated review. Cochrane Database Syst Rev. 2022;3(3):CD002120.
12. Aljasem B, Almeri A. Vitamin E supplementation and quality of life in women with primary dysmenorrhea: a prospective study. BMC Womens Health. 2024;24(1):58.
13. Rajput V. An overview on dysmenorrhea. Int J Nurs Educ Res. 2021;9(3):381-4.
14. Matsas A, Sachinidis A, Lamprinou M, Stamoula E, Christopoulos P. Vitamin effects in primary dysmenorrhea. Life. 2023;13(6):1308.
15. Sadiqa F, Fatimah M, Rehan AM, Mushtaq S, Firdous A, Jalal A. Comparative study on vitamin E & mefenamic acid versus mefenamic acid alone on mean reduction in pain in patients with primary dysmenorrhea. Pak J Med Health Sci. 2021;15(12):3195-7.
16. Ilyas A, Iqbal S. Comparison of mean pain score with vitamin e in combination with mefenamic acid versus mefenamic acid alone for management of primary dysmenorrhea. Pak J Med Health Sci. 2019;13(1):96-8.
17. Khan M, Ahmed S, Raza M. Comparative analysis of complementary therapies for primary dysmenorrhea in South Asia: a cost-benefit approach. J Altern Complement Med. 2023;29(6):512-9.
18. Bano R, Akhtar A, Yasmin H. Efficacy of vitamin E versus mefenamic acid in primary dysmenorrhea: a randomized controlled trial. J Coll Physicians Surg Pak. 2022;32(4):445-9.
19. Chen L, Wang H, Zhang Y. Prostaglandin levels and uterine contractions in the pathogenesis of primary dysmenorrhea. Reprod Sci. 2021;28(8):2154-62.
20. Smith RP. Gynecology in primary care: dysmenorrhea management and NSAID tolerability. Prim Care Clin Office Pract. 2021;48(2):211-22.
21. Hashim RT, Hamdan FB, Al-Salman AS. Oxidative stress and antioxidant status in primary dysmenorrhea: a cross-sectional study. J Obstet Gynaecol Res. 2021;47(10):3550-7.
22. Imai A, Takagi H, Matsunami K, Tamaya T. Oxidative stress biomarkers in primary dysmenorrhea: a systematic review. Reprod Med Biol. 2023;22(1):e12462.
23. Patel V, Surti A. The role of dietary supplements and antioxidants in menstrual disorders. Int J Gynecol Obstet. 2022;158(1):45-52.
24. Abu HF, Ali SS. Vitamin E supplementation and inflammatory markers in reproductive-age women: a randomized trial. Eur J Nutr. 2024;63(2):411-20.
25. Abu Helwa HA, Mitaeb HA, Al-Hamow H, Shamsudeen A. Impact of dysmenorrhea on academic performance and absenteeism among university students. Eur J Obstet Gynecol Reprod Biol. 2020;245:120-5.
26. Zafari M, Tofighi M. Long-term efficacy of antioxidant therapy in the management of primary dysmenorrhea: a 6-month follow-up study. J Obstet Gynaecol. 2024;44(1):2310456.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ameena Zahid, Nidda Yaseen, Nadia Naheed, Arfa Awaan, Shahzeen Aftab Alvi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
